Lipids & metabolic liver disease
Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies
Authors' conclusion
In this diagnostic study of the type 2 diabetes mellitus population, FIB-4 and APRI showed better performance for identifying advanced fibrosis in MAFLD with mixed etiologies.
Study context
- Population
- Inpatients with T2D and MAFLD; mean (SD) age 58.4 (13) years, 835 (56.6%) males
- Participants
- 1,475 inpatients
- Comparison
- Performance of FIB-4, NFS and aminotransferase to platelet ratio index (APRI) for advanced fibrosis in MAFLD-M vs MAFLD-P
- Outcome
- Diagnostic performance (AUC, sensitivity, specificity) of FIB-4, NFS and APRI for advanced fibrosis
Methodological detailsmulticentre
- Multicentre
Performance
As reported in the abstract
AUC for advanced fibrosis
| Test or model | FIB-4 AUC | APRI AUC | NFS AUC | FIB-4 sensitivity | APRI sensitivity |
|---|---|---|---|---|---|
| MAFLD-M | 0.680 | 0.723 | 0.572 | 69.6% | 43.5% |
| MAFLD-P | 0.591 | 0.631 | 0.617 | 54.0% | 26.1% |
FIB-4 AUC
MAFLD-M0.680
MAFLD-P0.591
APRI AUC
MAFLD-M0.723
MAFLD-P0.631
NFS AUC
MAFLD-M0.572
MAFLD-P0.617
FIB-4 sensitivity
MAFLD-M69.6%
MAFLD-P54.0%
APRI sensitivity
MAFLD-M43.5%
MAFLD-P26.1%
- MAFLD-M vs MAFLD-P: P = 0.0442
- MAFLD-M vs MAFLD-P: P = 0.0363
- MAFLD-M vs MAFLD-P: P = 0.3237 — no significant difference
- MAFLD-M vs MAFLD-P: P = 0.019
- MAFLD-M vs MAFLD-P: P = 0.005
Original publication
Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies. Endocr Pract. Published 5 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →